# A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

> **NCT03783442** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 649 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Oxaliplatin
- **DRUG:** Fluorouracil (5-FU)
- **DRUG:** Capecitabine
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Tislelizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03783442
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-11
- **Primary completion:** 2022-02-28
- **Final completion:** 2024-08-22
- **Target enrollment:** 649 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03783442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03783442, "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03783442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*